NorthStar’s Accelerator Production facility expansion is nearing completion in Beloit, Wisconsin, with the first pair of IBA accelerators due to arrive from Belgium in early April 2021.
They will be used for the production of non-uranium based Mo-99, which enables NorthStar’s FDA-approved and commercially available RadioGenix® System (technetium Tc 99m generator) to produce Tc-99m in the United States. The collaboration builds on an existing contract under which IBA is providing NorthStar with up to eight Rhodotron® TT 300-HE electron beam accelerators. The collaboration enables companies outside of the United States to access the Tc-99m Generation Systems (TCM Generation Systems) that utilize NorthStar’s proprietary non-uranium based Mo-99 produced using IBA’s accelerators and beamlines. Louvain-La-Neuve, Belgium, and BELOIT, Wis., USA March 8, 2021 – IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, and NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, today announced a collaboration to increase global availability of technetium-99m (Tc-99m), the most widely used medical radioisotope. − Diagnostic imaging studies using Tc-99m inform healthcare decisions for approximately 30 million patients annually around the world − Collaboration enables integrating technology expertise to provide Tc-99m Generation Systems (TCM Generation Systems) that utilize non-uranium based Mo-99 produced using electron beam accelerators − Technetium-99m is the daughter isotope of molybdenum-99 (Mo-99)
0 kommentar(er)
